Taiwan · Taiwan Food and Drug Administration · Generics
Review target
210 days
performance goal
Legal time limit
-
Not published
Steps
5
8 requirements
Application fee
NT$140,000
Fee standard in force since 2021-01-01
Registration of a product with the same ingredient, dosage form, strength and indication as a drug already approved in Taiwan. The usual evidence is a bioequivalence study, plus a patent linkage declaration. Copies of approved small molecule drugs.
The official review target is 210 days (performance goal). Time the applicant takes to answer questions (clock stops) is not counted. Targets are not actual review times.
The generic registration fee, product under safety monitoring is NT$140,000 for Fee standard in force since 2021-01-01.
1. Submit the application; 2. Administrative and technical review; 3. Applicant supplies missing data (clock stopped); 4. Decision; 5. Collect the drug license.
Outcome: Drug license valid for 5 years and renewable. Valid for 5 years.
Legal basis: Pharmaceutical Affairs Act Chapter 4-1 (patent linkage); Regulations for Registration of Medicinal Products Articles 4, 37 and 40
Each box is one step; arrows show the order. Dashed boxes happen only in some cases; the orange arrows go back (for example after questions).
About 91 days end to end with the official step targets, of which up to 61 days are clock stops (time the applicant uses to answer). Targets, not actual times.
In order, with the official target for each step
What the applicant must provide or meet
Targets, not actual review times
| Review targetperformance goal. Official processing period in calendar days, as announced by the TFDA. It is a target, not an actual review time. | 210 days |
Official amounts in the local currency
| Fee | Amount |
|---|---|
| Generic registration fee, product under safety monitoringApplication · Fee standard in force since 2021-01-01 | NT$140,000 |
| Generic registration fee, other productsApplication · Fee standard in force since 2021-01-01 | NT$80,000 |
| Bioequivalence study report review feeOther · Fee standard in force since 2021-01-01 | NT$60,000 |
Other routes in Taiwan: New drug registration, new active substance, New drug registration, known ingredient (new combination, route, dosage form, dose or strength), New indication or new dosage change, New drug priority review, New drug accelerated approval, New drug streamlined review (reliance on US, EU and Japan approvals), Breakthrough therapy designation, Designation for drugs for pediatric or rare severe diseases, Special approval to make or import unlicensed drugs. See all routes on the Taiwan page or explore them in the Regulatory section.
Not legal or regulatory advice. Check the current official rules before you act. This summary was checked against the official laws, regulations and regulator guidance on October 3, 2026 (18 facts checked). Parts of the approvals data are official open data reused under open licences. Data sources.